Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Genitourinary 2Dermatologic 2Thoracic 1Gastrointestinal 1Breast 1

Conditions

Colorectal Neoplasms 55Neoplasms 31Unspecified Adult Solid Tumor, Protocol Specific 30Pancreatic Neoplasms 28Neoplasm Metastasis 24Colonic Neoplasms 23Stomach Neoplasms 22Rectal Neoplasms 20Neuroblastoma 15Lung Neoplasms 13Esophageal Neoplasms 12Glioblastoma 11Central Nervous System Neoplasms 11Carcinoma, Non-Small-Cell Lung 11Brain Neoplasms 11Astrocytoma 11Small Cell Lung Carcinoma 9Glioma 9Oligodendroglioma 8Gliosarcoma 8Breast Neoplasms 8Esophageal Squamous Cell Carcinoma 7Adenocarcinoma 7Unspecified Childhood Solid Tumor, Protocol Specific 6Ovarian Neoplasms 6Gallbladder Neoplasms 6Carcinoma, Hepatocellular 6Bile Duct Neoplasms 6Triple Negative Breast Neoplasms 5Solid Tumor 5

Interventions

Carboplatin 40Paclitaxel 30Bevacizumab 16Gemcitabine 14Cyclophosphamide 14liposomal doxorubicin 13Taxes 12Topotecan 11Cisplatin 11Docetaxel 7veliparib 6pembrolizumab 6olaparib 6Doxorubicin 6Magnetic Resonance Spectroscopy 5Albumin-Bound Paclitaxel 5sargramostim 4fludarabine 4aldesleukin 4Specimen Handling 4Oxaliplatin 4Leucovorin 4Immunoglobulin G 4Filgrastim 4Drug Therapy 4Disulfides 4Biopsy 4talazoparib 3mirvetuximab soravtansine 3Radiotherapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Fallopian Tube Neoplasms × Irinotecan × Clear all
NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Toray Industries, Inc

Phase 1 Active not recruiting
138 enrolled
DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡